Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon gamma-1b + donor leukocyte infusion
- Development stage
- Unknown
- Lead developer
- Sawa Ito
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Cell Therapies
- Administration
- Subcutaneous, Intravenous
01
Overview
This investigational immunotherapy combination regimen consists of recombinant interferon gamma-1b (marketed as Actimmune) and donor leukocyte infusion (DLI). Developed by Dr. Sawa Ito at the UPMC Hillman Cancer Center, the treatment is designed for patients with relapsed acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) following allogeneic hematopoietic stem cell transplantation (alloSCT). The therapeutic mechanism involves the administration of interferon-gamma to upregulate HLA expression and other interferon-inducible molecules on the surface of leukemia blasts. This process sensitizes the malignant cells to alloreactive T-cell-mediated killing, thereby enhancing the graft-versus-leukemia (GVL) effect when combined with the subsequent infusion of donor-derived lymphocytes. A Phase 1 pilot trial demonstrated safety and high remission rates, leading to an ongoing Phase 2 trial to confirm efficacy.
- Brand names
- Actimmune
- Other names
- IFN-gamma + DLIInterferon-gamma + Donor Leukocyte Infusion
02
Targets
IFNGR2 (Interferon gamma receptor 2)IFNGR1 (Interferon gamma receptor 1)
Beyond the preview
Go deeper on interferon gamma-1b + donor leukocyte infusion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon gamma-1b + donor leukocyte infusion.